Magnesium L-Threonate
SupplementThe divergence of -20 points is explained by the limited clinical evidence base (few, partly industry-funded RCTs with small sample sizes) [s1, s3] versus the predominantly positive user feedback in biohacking communities [c1, c2, c3], which is more susceptible to placebo effects and selection bias.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Magnesium L-threonate is the most expensive magnesium form with the most specific claim: superior blood-brain barrier penetration for cognitive effects. Three human RCTs (n=44–109) show moderate improvements in cognition and sleep, but at least two are industry-funded (Magtein®) and independent replication is still absent. In the EU, it only received Novel Food approval in October 2024, with market exclusivity for AIDP Inc. until 2029. Anyone primarily targeting sleep or muscle cramps gets stronger evidence for significantly less money with glycinate.
Description
Magnesium L-threonate is a magnesium compound designed to cross the blood-brain barrier, potentially supporting cognitive function, memory, and sleep quality [s1, s2].
Magnesium L-threonate (MgT) is a compound of magnesium and L-threonic acid, a metabolite of vitamin C. The compound was developed by neuroscientists at MIT with the goal of efficiently transporting magnesium into the brain. Unlike other magnesium forms such as oxide, citrate, or glycinate, magnesium L-threonate demonstrates significantly higher accumulation in cerebrospinal fluid and neuronal tissue in animal studies [s4, s5]. In human studies, improvements in overall cognitive performance, working memory, reaction time, sleep quality, and stress regulation have been observed [s1, s2, s3]. The substance is patented as Magtein® and is included in numerous commercial nootropic products. The evidence base in humans remains limited (few RCTs, predominantly with industry involvement), while animal studies show more robust effects, including neuroprotective actions in Alzheimer's mouse models [s7, s8]. The elemental magnesium content in typical daily doses (1440–2000 mg MgT) is approximately 140–200 mg elemental magnesium, which is well below the tolerable upper intake levels set by EFSA and BfR [s12, s13]. The EU Novel Food authorization permits use exclusively for adults in food supplements [s12].
Legal Status (DE)
Since 17 October 2024, magnesium L-threonate has been authorized in the EU as a Novel Food under Implementing Regulation (EU) 2024/2694 and may be placed on the market as a food supplement [s12]. AIDP Inc. holds market exclusivity in the EU until November 2029 [s12]. In the USA, Magtein® is considered GRAS (since 2012, FDA Letter of No Objection 2014) [s11].
Mechanism of Action
Magnesium L-threonate utilizes L-threonic acid as a transport vehicle, delivering magnesium across the blood-brain barrier into cerebrospinal fluid and neuronal structures via glucose transporters (GLUTs) [s5]. Preclinical studies show that MgT increases magnesium concentration in cerebrospinal fluid significantly more than equimolar doses of other magnesium forms (e.g., magnesium chloride, gluconate) [s4, s5]. At the molecular level, magnesium voltage-dependently blocks NMDA glutamate receptors, regulating the threshold for long-term potentiation (LTP) — the cellular mechanism underlying learning and memory consolidation [s6]. Elevated cerebral magnesium concentration thereby enhances synaptic plasticity, increases synaptic density, and promotes neurogenesis in the hippocampus [s7, s8]. Additionally, magnesium modulates GABA-A receptors and inhibits excitatory glutamatergic transmission, which may account for anxiolytic and sleep-promoting effects [s6]. In Alzheimer's mouse models, MgT reduced amyloid deposits, improved intestinal barrier integrity, and modulated the microbiota-gut-brain axis [s7, s8]. The precise relevance of these findings to humans has not yet been established by clinical studies.
Dosing
Kognitive Funktion und Gedächtnis
- Dose
- 1440–2000 mg magnesium L-threonate (equivalent to approx. 144–200 mg elemental magnesium)
- Frequency
- 1× täglich oder aufgeteilt auf 2 Dosen
- Route
- oral
- Duration
- 6–12 Wochen, dann Neubewertung
- Timing
- Morning or split morning/midday; evening intake may increase sleep latency in sensitive individuals
- With food
- optional
Schlafqualität
- Dose
- 1000–2000 mg magnesium L-threonate
- Frequency
- 1× täglich abends
- Route
- oral
- Duration
- 8 Wochen
- Timing
- 30–60 minutes before bedtime; switch to morning intake if paradoxical stimulation occurs
- With food
- optional
Angst und Stressreduktion
- Dose
- 1440–2000 mg magnesium L-threonate
- Frequency
- 2× täglich (Morgen und Mittag)
- Route
- oral
- Duration
- 8–12 Wochen
- Timing
- Not shortly before bedtime in individuals sensitive to stimulation
- With food
- optional
The EFSA assessment and EU Novel Food authorization do not set a specific upper limit for total MgT dose; however, they recommend limiting elemental magnesium intake from supplements to a maximum of 250 mg/day to minimize gastrointestinal risk [s12, s13]. The BfR recommends a maximum of 250 mg elemental magnesium daily from supplements [s13].
A daily dose of 2000 mg MgT provides approximately 200 mg elemental magnesium, which is within the BfR recommendation. The L-threonate component itself is rapidly absorbed and metabolized with no currently known long-term toxicity [s9].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Kopfschmerzen Reported by some participants in clinical studies; possibly attributable to altered cerebral magnesium or glutamate levels [s1, s9]. | gelegentlich | leicht |
| Tagesmüdigkeit oder Schläfrigkeit NMDA blockade and GABAergic modulation can cause sedation in sensitive individuals, particularly at higher doses [s6, c1]. | gelegentlich | leicht |
| Paradoxe Schlafstörung / Schlaflatenz bei Abendeinnahme Multiple users report that evening intake leads to increased mental activation rather than relaxation, attributed to the cognitively stimulating component of its action [c1, c4]. | gelegentlich | leicht |
| Leichte gastrointestinale Beschwerden (weicher Stuhl, Übelkeit) Less common compared to osmotically active magnesium forms (oxide, citrate), as absorption via glucose transporters is more efficient and gentler [s4, s13]. | selten | leicht |
| Allergische Reaktion Rare individual cases of allergic reactions have been mentioned in the literature, without causal confirmation in RCTs [s10]. | selten | moderat |
| Hypermagnesiämie (bei exzessiver Dosierung oder Niereninsuffizienz) No realistic risk at daily doses within recommended limits and normal renal function. At GFR < 30 mL/min or with excessive supplementation, magnesium can accumulate [s13]. | theoretisch | schwer |
Contraindications
Impaired renal magnesium excretion increases the risk of hypermagnesemia with symptoms such as bradycardia, respiratory depression, and neuromuscular blockade [s13].
Magnesium inhibits presynaptic acetylcholine release at the neuromuscular junction, which may exacerbate muscular weakness in myasthenia gravis [s13].
Magnesium forms chelate complexes with these antibiotics, significantly reducing their bioavailability. Maintain a minimum interval of 2 hours [s13].
The EU Novel Food authorization explicitly excludes pregnant and breastfeeding women from the approved scope of use, as sufficient safety data are lacking [s12].
EU approval restricts use to adults. No pediatric safety data available for MgT [s12].
Interactions
Synergistic
L-threonate is a vitamin C metabolite; theoretical mutual support of antioxidant capacity, no direct RCT evidence [s5].
Some users report synergistic sleep support from GABA supplements combined with MgT; no RCT evidence, clinical caution warranted regarding potential additive sedation [c4].
Caution
Chelate complex formation significantly reduces antibiotic absorption. A minimum administration interval of 2 hours is recommended [s13].
Magnesium ions can chelate bisphosphonates and impair their gastrointestinal absorption [s13].
Additive calcium antagonistic effect possible; theoretical potentiation of blood pressure reduction and cardiac conduction delay [s13].
Studies
Tier A — High Evidence
Outcome: Sleep quality and daytime functioning in adults with self-reported sleep problems
Effect Size: Significant improvement in PSQI score and subjective daytime energy; no significant improvement in objective polysomnography parameters
Outcome: Cognitive dysfunction, sleep, and anxiety in older adults (50–70 years)
Effect Size: Improvement in overall cognitive score; average reduction in cognitive age by ~9 years; improvement in sleep and anxiety scores
Outcome: Overall cognitive performance, cognitive age, working memory, reaction time, sleep quality
Effect Size: Significant improvement in overall cognitive performance and working memory vs. placebo; subjective but not objective sleep parameters improved (Magtein® 2000 mg/day)
Tier B — Moderate Evidence
Outcome: NMDA receptor blockade, synaptic plasticity, learning mechanisms
Effect Size: Mechanistic review; no direct effect size value
Outcome: Safety and bioavailability of magnesium L-threonate as a novel food
Effect Size: Safe under conditions of use; bioavailability of Mg comparable to other magnesium salts
Tier C — Low Evidence
Outcome: Intestinal barrier function, microbiota-gut-brain axis, cognitive manifestations
Effect Size: MgT repaired intestinal barrier dysfunction and reduced cognitive symptoms in the model
Outcome: Hippocampal neurogenesis, memory deficits
Effect Size: MgT improved neurogenesis and attenuated memory deficits in an AD mouse model
Outcome: CSF magnesium levels following MgT vs. other Mg forms
Effect Size: MgT significantly increased CSF Mg more than MgCl₂ or Mg gluconate
Community Evidence
Top reported benefits
- Enhanced executive function and focus
- Better sleep quality (especially deep sleep)
- Reduced anxiety and nocturnal rumination
- Reduced restless legs symptoms
- Increased mental clarity and productivity
Top reported issues
- Paradoxical stimulation and worsening of sleep with evening administration
- High price compared to other magnesium forms
- No noticeable effect in a subset of users
- Next-day drowsiness at higher doses
- Reported unpleasant combination with caffeine
A minority of users report increased cerebral activity with evening dosing, reversing the desired sleep effect [c1, c4]. Additionally, the industry funding of Magtein® studies is critically discussed within the community. The high cost compared to glycinate or citrate is frequently cited as a barrier. Some neurodivergent users report intolerance or exacerbated symptoms [c2].
Scientific Sources
- The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial
Lopresti AL, Smith SJ, et al. (2025). Frontiers in NutritionAPMID:41601871DOI - Magnesium-L-Threonat: Nebenwirkungen und Verträglichkeit
Supplementinspektor Editorial (2023). Supplementinspektor.deDLink - AIDP's Magtein confirmed GRAS
New Hope Network Editorial (2014). New Hope NetworkBLink - Durchführungsverordnung (EU) 2024/2694 der Kommission vom 17. Oktober 2024 zur Genehmigung des Inverkehrbringens von Magnesium-L-Threonat als neuartiges Lebensmittel
Europäische Kommission (2024). Amtsblatt der Europäischen UnionALink - Magnesium – was ist zu beachten?
Verbraucherzentrale Deutschland (2023). Verbraucherzentrale.de / Klartext NahrungsergänzungBLink - Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-Analysis
Kirkland AE, Sarlo GL, Holton KF, et al. (2024). PMC / NutrientsALink - Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial
Zhang C, Hu Q, Li S, et al. (2024). Sleep MedicineAPMID:39252819DOI - Enhancement of Learning and Memory by Elevating Brain Magnesium
Slutsky I, Abumaria N, Wu LJ, et al. (2010). NeuronCPMID:20152124DOI - Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model
Li W, Yu J, Liu Y, et al. (2014). Molecular BrainCPMID:24484742DOI - Can Magnesium L-Threonate (NeuroMag™) Help Clear Brain Fog in Long COVID and ME/CFS?
RTHM Editorial (2023). RTHM Clinical ResourcesBLink - Magnesium transport across the blood-brain barriers
Height S, et al. (2018). Magnesium in the Central Nervous System – NCBI BookshelfBLink - Magnesium-L-threonate treats Alzheimer's disease by modulating the microbiota-gut-brain axis
Cai X, Huang Z, Liu Y, et al. (2024). Neural Regeneration ResearchCPMID:38488562DOI - Magnesium-L-threonate Ameliorates Cognitive Deficit by Attenuating Adult Hippocampal Neurogenesis Impairment in a Mouse Model of Alzheimer's Disease
Fan X, Zhang L, Li H, et al. (2024). CNS Neuroscience & Therapeutics / PMCCLink - Safety of magnesium l-threonate as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of magnesium from this source in the context of Directive 2002/46/EC
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) (2024). EFSA JournalADOI
Community Sources
Storage
Unopened
Store in a dry, cool location at room temperature (15–25 °C), protected from direct sunlight and moisture.
Opened
Seal container tightly after use; no additional precautions required for capsule forms.
Notes
MgT is hygroscopic; powder forms must be protected from moisture ingress in particular.